Finally, a family friend who worked as a healthcare provider in urgent care took her concerns seriously, ordered tests, and asked if she’d ever had an MRI. Within a month, Chelsea had her first scan ...

Objective: To describe two cases of recurrent, delayed-onset severe neutropenia several months following ocrelizumab therapy in patients with relapsing–remitting multiple sclerosis (RRMS). Background: ...

It's a new dawn for MSNBC, which is being rebranded and will now be known as MS NOW. The transition comes as the channel breaks off from its current parent company, Comcast NBCUniversal, and moves to ...

Trial tests drug against relapsing form of the disease Drug candidate as effective as Roche's Ocrevus in a separate study Fenebrutinib could bring in over $1 billion in annual peak sales FRANKFURT, ...

Roche has reported wins for its BTK inhibitor fenebrutinib in a pair of phase 3 studies across two multiple sclerosis (MS) populations. One victory was based on the finding that the candidate was ...

I’d spent about five years trying to figure out what was wrong with me and then treat it when I got the phone call. During that time, I’d had three surgeries to repair old injuries and had been ...

BARCELONA, Spain — Annual dosing of rituximab for relapsing-remitting multiple sclerosis (RRMS) was noninferior to the typical dosing schedule of once every 6 months, which could offer a more ...

Eyeing a drug that it believes holds peak annual sales potential of $12 billion in the U.S. alone, Zenas BioPharma has struck a licensing deal with China-based InnoCare Pharma that could be worth more ...

Recent research on fluid biomarkers in multiple sclerosis (MS) frames an emerging picture of two aspects of the disease: inflammatory activity measured with neurofilament light chain (NfL), and ...

Share on Pinterest Subtle signs of multiple sclerosis may appear more than a decade before onset, recent research suggests. Image credit: Pancake Pictures/Getty Images Research is ongoing regarding ...

Andy Biggs and Karrin Taylor Robson have never seen me. Not when I was a healthy, working Tucsonan. Not when multiple sclerosis began attacking my central nervous system four years ago. And certainly ...